Tumor-tropic neural stem cells (NSCs) can be used in the Trojan horse approach as cellular vehicles for targeted delivery of therapeutic agents to distant tumor sites. To realize this cancer therapy potential, it is important to have a renewable source to generate large quantities of uniform human NSCs. Here, we reported that NSCs derived from HES1 human embryonic stem cell line were capable of migrating into intracranial glioma xenografts after systemic injection or after intracranial injection at a site distant from the tumor. To test whether the HES1-derived NSCs can be used for cancer gene therapy, we used a baculoviral vector to introduce the herpes simplex virus thymidine kinase suicide gene into the cells and demonstrated that baculovirusmediated transgene expression may last for at least 3 weeks in NSCs. After being injected into the cerebral hemisphere opposite the tumor site and in the presence of ganciclovir, NSCs expressing the suicide gene were able to inhibit the growth of human glioma xenografts and prolong survival of tumor-bearing mice. Our findings suggest that human embryonic stem cells could potentially serve as a clinically viable source for production of cellular vehicles suitable for targeted anticancer gene therapy.
INTRODUCTION
Neural stem/progenitor cells (NSCs) are multipotent cells in the nervous system that can differentiate to yield the three principle types of neural cells-neurons, astrocytes and oligodendrocytes. NSCs are capable of spreading through the existing migratory pathways in a healthy brain. When tumors are present, NSCs can migrate through non-typical routes and home in on tumor foci. 1, 2 The intrinsic tropism of NSCs for tumors has been utilized extensively for targeted delivery of therapeutic agents to glioma, non-glial brain tumors as well as solid tumors of a nonneural origin in animal tumor models. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] These studies have suggested a powerful therapeutic approach of using NSCs to target not only the major tumor mass, but also distant tumor outgrowths.
To introduce therapeutic genes into NSCs, many studies utilized integrating viruses, such as lentivirus or retrovirus, to instigate stable expression of therapeutic transgenes. 8, 9, [13] [14] [15] These viruses are well known to preferentially integrate into transcriptionally active regions of host genomes, raising concerns over insertional mutagenesis, oncogene activation and cellular transformation. [16] [17] [18] Baculoviral vectors derived from an insect virus Autographa californica multiple nucleopolyhedrovirus, on the other hand, are non-integrating and mediate transient transgene expression in human cells. This insect virus is emerging as a potentially safe class of gene delivery vectors because of its inability to replicate or cause toxicity in mammalian cells. [19] [20] [21] [22] [23] Baculovirus-derived vectors are capable of transducing both dividing and non-dividing cells including human embryonic stem cells (hESCs) 24, 25 and mesenchymal stem cells. 26, 27 The great potential of NSCs in cancer therapy highlights the need for consistent and renewable sources for the collection or production of uniform human NSCs suitable for clinical applications. Fetal or adult human brain tissues provide one possible source of primary human NSCs. 28, 29 However, derivation of primary NSCs from the adult human brain is an extremely invasive procedure and the procedure while derivation of NSCs from fetuses generates ethical and regulatory issues. As cell therapy products, primary human NSCs are variable in quality and hold limited passaging capacity, posing many challenges for largescale preparation of cells with stable characteristics. Although oncogenemediated immortalization provides a means to overcome the drawback of limited lifespan of primary human NSCs, the well-documented oncogenic potential of these genes 30 poses safety concern over cell therapy applications using these immortalized human NSC lines.
The ability of hESCs to generate virtually any differentiated cell type provides the possibility of using these cells as a new source of human NSCs. Self-renewing hESCs are inherently immortal with preserved proliferation capacity in long-term cell culture. Consequently, hESCs can be used as a reliable and accessible source to generate unlimited amounts of human NSCs. Standardization in large-scale mass production of hESC-derived cells offers the potential for the manufacture of uniform batches of cell therapy products sufficient for repeated treatments in multiple patients. This will help eliminate variability in the quality of cell therapeutics and facilitate reliable comparative analysis of clinical outcomes. Large-scale manufacture of human NSCs from hESCs, instead of collecting and expanding primary cells from individual patients, is foreseen to reduce the laboriousness and simplify the logistics of cell-culture operations, thus increasing cost effectiveness. It should also be possible to prepare cryopreserved hESC-derived NSCs in ready-to-go format.
R E T R A C T E D A R T I C L E
Several methods have been developed so far to enable the differentiation of NSCs from hESCs. [31] [32] [33] [34] These hESC-derived NSCs are similar to adult NSCs in their gene expression profile, surface marker profile and potential in differentiating into neuron, astrocytes and oligodendrocytes. 34 They exhibit much greater proliferative capacity than their adult counterparts, and could be consistently derived in large amounts. However, it remains unclear whether hESC-derived NSCs migrate toward tumors and can eliminate tumor cells effectively after being loaded with therapeutic gene products. To address this issue, we derived NSCs from the HES1 human embryonic stem cell line and employed baculoviral transduction to load the NSCs with the herpes simplex virus thymidine kinase (HSVtk) suicide gene. Here, we report that hESC-derived, HSVtk-expressing NSCs are effective in targeting human glioma xenografts and delivering prodrug-converting enzyme for cancer gene therapy in a mouse model.
RESULTS
Generation of self-renewing NSCs from hESCs in adherent monoculture Using a simple adherent monoculture method, 35, 36 human NSCs were generated from HES1 hESCs in a defined adherent culture condition containing basic fibroblast growth factor (bFGF) and epidermal (Figure 1a ). After 3-4 weeks of adherent culture, cells started to form rosette-like structure, a typical morphology of neural differentiation. With further expansion, homogenous bipolar NSCs were achieved and named NSC1 ( Figure 1a ). The doubling time of NSC1 cells was B3-4 days and the culture was routinely passaged into two, twice per week. The NSC1 cells could be continuously cultured for at least 6 months. Furthermore, NSC1 cells could be cryopreserved in an NSC medium containing 10% dimethyl sulfoxide and remain viable after liquid nitrogen storage.
To characterize NSC1 cells, we examined the expression of neural progenitor markers and neural multipotency of these cells. Immunocytochemistry analysis showed that NSC1 cells were positive for nestin, NCAM and A2B5 ( Figure 1b ). Nestin is an early-stage NSC marker, NCAM is a late-stage neural lineage stem cell marker and A2B5 is a glial lineage marker. Quantitative fluorescence-activated cell sorting analysis revealed that 98, 91 and 97% of NSC1 cells were nestin, NCAM and A2B5 positive, respectively ( Figure 1c ). Gene expression profiles of HES1 and NSC1 cells were studied using human stem cell RT2 Profiler PCR Arrays (Table 1) . Among nine embryonic cell lineage markers, four were downregulated and four were not affected in NSC1 cells, with only one marker (MSX1)
showing upregulation. Most of lineage markers for hematopoietic cells and mesenchymal cells were either not affected or downregulated, but gene expression of MME and COL1A1 was upregulated. Especially, the mesenchymal cell lineage marker COL1A1 was upregulated 250-fold (Table 1) . This extracellular matrix protein gene is known to be expressed by both adult neuroprogenitors and mesenchymal stem cells. 37 When looking at neural cell lineage markers, three (CD44, NCAN1 and OPRS1) out of five markers were upregulated, S100B showed no change and TUBB3 was downregulated (Table 1) . Reverse transcription-PCR analysis further confirmed that NSC1 cells did not express pluripotent stem cell markers Oct-4 and Nanog, mesoderm marker Brachyury T and endoderm marker AFP (Figure 1d ). When transferred to suspension culture in a low-cell binding plate in culture medium containing bFGF and EGF, NSC1 cells formed neurospheres ( Figure 1a ). After sequential withdrawal of bFGF and EGF, they generated mixed populations of b-III tubulin-positive neurons and glial fibrillary acidic protein (GFAP)-positive glial cells ( Figure 1e ). These results demonstrated that NSC1 cells are in high purity and possess the potential to differentiate into neurons and glial cells. In addition to HES1 cell line, we were able to use the same method to generate NSCs from two other hESC lines, HES3 and H1, successfully (data not shown).
Glioma-specific migration ability of NSC1 cells
The glioma tropism of primary NSCs and NSC lines has been well documented. To examine the selective tropism of NSC1 cells for glioma, we seeded human glioma U87 and H4 cells and non-tumor human kidney 293FT cells, respectively, into the lower Boyden chamber as attractants and determined the migration of NSC1 cells. Mouse C17.2 NSCs and mouse 3T3 fibroblast cells were included as a positive NSC control and as a negative cell control, respectively, in our migration assay. As observed under a fluorescence microscope ( Figure 2a ) and quantified using a fluorescence microplate reader (Figure 2b ), both NSC1 and C17.2 cells displayed high migration capacities toward human glioma U87 and H4 cells, but not to human kidney 293FT cells. Comparatively, far fewer 3T3 cells than NSC1 or C17.2 cells migrated toward glioma cells, and there was no significant difference between the migration of 3T3 cells toward glioma and non-glioma cells. When comparing the glioma-directed migration of NSC1 and C17.2 NSCs, NSC1 cells migrated more extensively than C17.2 cells. The strong tropism of hESC-derived NSCs toward glioma cells suggests that these cells are well suited as delivery vectors for glioma gene therapy.
To examine the in vivo glioma tropism of NSC1 cells, an intracranial glioma model was generated by injection of the U87 human glioma cells into the right striatum of nude mice and DiR-labeled NSC1 cells were injected into the contralateral striatum 7 days later ( Figure 3a ). We first used whole-animal imaging to monitor the transparenchymal migration of NSC1 toward the U87 tumor. Although the positions of near-infrared fluorescent signal of DiR shifted toward the tumor side, the changes were not obvious ( Figure 3b ). Ex vivo imaging of isolated mouse brains was then performed. Images of the brains collected on days 7 and 14 after NSC1 injection showed that DiR signals were detectable in the U87 glioma within 1 week, indicating that NSC1 cells had migrated through the brain parenchyma to reach the tumor site in the opposite hemisphere. As revealed by quantitative analysis, around 20 and 25% of NSC1 cells had homed into the tumor by days 7 and 14, respectively ( Figure 3c ). There was no obvious migration of NSC1 cells in the control mice without U87 inoculation.
To perform histological examination, we labeled U87 cells with the green fluorescent dye DiO and NSC1 cells with the red fluorescent dye CM-DiI. We observed extensive colocalization of NSC1 cells with the 
tumor mass in the sections of the brains collected on day 14 after NSC1 injection ( Figure 4a ). Many NSC1 cells had penetrated several hundreds of micrometer into the tumor mass. We also performed immunostaining to examine homing of NSC cells to the tumor site. To examine whether genetic modification affect the migration capacity of NSCs, NSC1 cells transduced by a baculoviral vector containing the HSVtk gene were injected into the contralateral side of U87 brain tumor. An antibody against human GFAP was used to stain migrating NSCs. As reported previously, tumor-tropic human NSC populations are strongly positive for GFAP, 38, 39 while in most human glioblastoma multiforme tumors, including the U87 tumor, the GFAP was not detectable due to hypermethylation of the GFAP promoter. 40, 41 We detected GFAP-positive cells in the U87 tumor ( Figure 4b ), which is strong evidence that the NSCs injected into the contralateral brain side had migrated into the tumor. In consistence with a previous report that the NSCs homed to glioma differentiate into astrocytes, 38 the GFAP-positive cells detected in the current study also display astrocyte-like morphology that totally differed from that of U87 tumor cells, providing morphological evidence of NSC homing in on the tumor.
To assess the suitability of the tail vein route in administering NSCs systemically, we injected CM-DiI-labeled NSC1 cells through the tail vein 1 week after intracranial injection of DiO-labeled U87 cells and collected the mice brains 1 week after NSC1 injection. Microscopic examination of brain sections confirmed the colocalization of NSC1 cells with the tumor mass ( Figure 4c ), indicative of NSC1 cells migration across the blood-brain barrier. The tail vein-injected NSC1 cells penetrated into the tumor mass well and distributed extensively throughout the intracranial tumor bed. CM-DiI signals from the tail vein-injected NSC1 cells were not obvious in peritumoral brain tissues or elsewhere in the brain. These in vivo results suggest that NSC1 cells can be used as cellular vehicles to target intracranial tumors, even after systemic administration.
Baculoviral vector-mediated transgene expression in NSC1 cells
To successfully use NSCs as cellular vehicles for cancer gene therapy, effective transduction to load cells with therapeutic genes and maintenance of transgene expression in the transduced cells long enough to achieve therapeutic effects are critical. In our previous studies, 24, 25, 42 a baculoviral vector with the cytomegalovirus promoter and the woodchuck hepatitis virus post-transcriptional regulatory element proved to be effective in transducing hESCs and hESC-derived human neurons and provided transgene expression in the derived neurons for up to 3 months. Here, we tested whether this baculoviral expression cassette with a gene encoding enhanced green fluorescent protein (eGFP) is efficient in genetic modification of hESC-derived NSCs. As shown in Figure 5 , very bright green fluorescence was observed in NSC1 cells at day 2 after transduction with this viral vector at a multiplicity of infection of 100, and almost 100% of NSC1 cells were eGFP positive as analyzed by flow cytometry. While we noted a drop in mean fluorescence intensity of eGFP-positive cells from 7709 units at day 2 to 920 units at day 21, the percentage of eGFP-positive cells only decreased slightly to 94% at day 21. These results demonstrated that baculoviral vectors with a cytomegalovirus/woodchuck hepatitis virus post-transcriptional regulatory element expression cassette can maintain transgene expression in NSC1 cells for at least 21 days.
Glioma therapy using HSVtk-expressing NSC1 cells The HSVtk/ganciclovir(GCV) system is commonly used in suicide gene therapy for cancer. In this approach, the HSVtk gene is delivered via either direct transduction or stem cell targeting of tumors. Within the tumor, HSVtk will phosphorylate GCV and the phosphorylated GCV exhibits strong bystander effect to interfere with DNA replication in tumor cells, thus resulting in their eventual death. 43, 44 To generate NSC1 cells suitable for cancer suicide gene therapy, we used a baculovirus vector containing a cytomegalovirus/woodchuck hepatitis virus post-transcriptional regulatory element cassette to drive the expression of the HSVtk gene in NSC1 cells. We confirmed HSVtk gene expression upon baculovirus transduction in NSC1 cells using western blotting ( Figure 6a ) and named these cells NSC1-tk cells.
To examine the in vitro bystander effect of phosphorylated GCV, cell viability tests were conducted in a co-culture system by mixing NSC1tk cells with U87 cells at a 1:1 ratio (Figure 6b ). Untransduced NSC1 cells, NSC1-tk cells alone and U87 cells alone were used as controls. GCV showed negligible toxicity to untransduced NSC1 cells and U87 cells. However, in NSC1-tk cells, GCV was cytotoxic at a concentration as low as 0.1 mg ml À1 , killing B50% of cells. The survival rate of these cells decreased with an increase in GCV concentration, o6% of NSC1-tk cells survived at a concentration of 10 mg ml À1 . Similarly, in the NSC1-tk and U87 co-culture system, cell viability was significantly reduced to 3% at 10 mg ml À1 of GCV. We compared the therapeutic efficacies of NSC1-tk cells transduced by the baculoviral vector 2 or 7 days before their co-culture with U87. NSC1-tk cells used at day 7 post-transduction showed enhanced cytotoxicity and bystander effects (Figure 6b ), probably due to accumulation of HSVtk in transduced cells. These findings have confirmed that baculovirus-
NSC1
Color Bar After NSC Injection We next examined the in vivo efficacy of NSC1-tk cells in eliminating U87 glioma cells. We established glioma xenografts in nude mice by inoculating U87-luc cells into the right striatum. Seven days later, the tumor-inoculated mice were divided into four groups (n¼10 per group). The experimental group received injection of NSC1-tk cells into the left striatum contralateral to the tumor inoculation site followed by daily intraperitoneal (i.p.) administration of GCV from day 14 to 35 post-tumor inoculation. Three control groups received intracranial injection of NSC1-tk cells with i.p. injection of phosphatebuffered saline (PBS), intracranial PBS injection followed by i.p. PBS injection, or intracranial PBS injection followed by i.p. injection of GCV. Tumor growth was monitored by bioluminescent imaging of U87-luc cells with the IVIS imaging system. Figure 7a shows brain images of representative U87-luc cell-bearing mice from four different groups at three different time points. The bioluminescence intensities, indicative of the tumor volume, demonstrate that NSC1-tk cell injection followed by i.p. GCV treatment produced more pronounced inhibitory effects on tumor growth compared with other treatments. Figure 4 Detection of glioma tropism of NSC1 cells in brain tissue sections. U87 and NSC cells were injected as illustrated in Figure 3a . (a) Migration of CM-DiI-labeled NSC1 cells after intracranial injection into U87 tumor. U87 cells were pre-labeled with DiO (green) and injected into the right striatum. CM-DiI-labeled NSC1 cells (red) were injected into the hemisphere contralateral to the U87 tumor cell inoculation site 7 days later. Brain sections were collected on day 14 after NSC injection. (b) GFAP immunostaining for the detection of NSC cells homed in on U87 tumor. NSC cells genetically modified to express the HSVtk gene (NSCtk) were used in the experiment. The left image shows no GFAP-positive cells in U87 tumor in a mouse inoculated with the tumor cells only, while the right image shows that GFAP-positive cells with astrocyte-like morphology (brown color) are detectable in U87 tumor in a mouse inoculated with the tumor cells followed by NSCtk injection 7 days later. (c) A brain section to show tail vein-injected, CM-DiI-labeled red NSC1 cells homing in on an intracranial U87 tumor stained with 4¢,6-diamidino-2-phenylindole (DAPI). The mouse brain was collected 14 days after U87 inoculation (7 days after NSC1 injection). At day 28, the bioluminescence intensity in the experimental group was B10% of those in the control groups (Figure 7b ). Attributed to the inhibitory effect on tumor growth provided by the NSC1-tk cell/GCV regime, the survival of the tumor-inoculated mice in this group was significantly prolonged (Figure 7c ; Table 2 ). The median survival time increased from 31 or 32 days for animals in the three control groups to 45 days in the NSC1-tk/GCV group. Statistical analysis revealed significant difference between the NSC1-tk/GCV group and other control groups, but no significant difference among the three control groups ( Table 2) . Histological examination (Figure 7d ) confirmed slower tumor development after NSC1-tk cell/GCV treatment and more rapid tumor growth in the control groups of animals. Thus, the NSC1-tk cell/GCV regime was powerful enough to slow down in vivo growth of glioma cells at a tumor site distant from the NSC1 cell injection site.
DISCUSSION
Recent years have seen the development of a variety of techniques enabling the differentiation of NSCs from ESCs. [31] [32] [33] [34] [35] [36] 45, 46 Most of the methods have used the formation of neurospheres or embryoid bodies. For example, NSCs could be generated by overgrowth of hESCs to a higher cell density. 31 After prolonged culture of hESCs, without changing the feeder cells for 3-4 weeks, NSC marker-positive cells are isolated mechanically and transferred into a serum-free medium to form neurospheres. Forming embryoid bodies is another way to induce neural differentiation of hESCs. 32, 45 The embryoid bodies are subsequently seeded onto an appropriate substrate in a defined medium containing mitogens to further select for the NSC population. However, the difficulty in handling cell aggregates limits large-scale generation of NSCs through the formation of neurospheres and embryoid bodies. A different reported technique directed differentiation of ESCs to NSCs by co-culture with mouse PA6 stromal cells. 46 However, exposure of human cell-based therapeutics to animal cells generates safety issues that forbid clinical applications. Recently, Smith's laboratory showed that simple plating of mouse and human ESCs in a monolayer culture could successfully generate NSCs. 35, 36 In this study, long-term proliferating NSCs were derived from HES1 hESCs using a monolayer culture condition that does not require cellaggregate formation. Ninety-seven percent of NSC1 cells were positive for the NSC marker nestin, indicating a high purity of NSCs from this production protocol. NSC1 cells formed neurospheres in suspension culture, which is a universally accepted standard for NSCs. Our reverse transcription-PCR analysis demonstrated that NSC1 cells do not express pluripotent stem cell-specific transcription factors Oct-4 and Nanog, mesoderm marker Brachyury T and endoderm marker AFP. PCR array analysis further showed upregulation of most of neural cell lineage markers, but downregulation of many lineage markers for embryonic cells, hematopoietic cells and mesenchymal cells. In vivo injection of stem cell therapeutics without contamination of hESCs is important in reducing the risk of tumorigenesis that is associated with the presence of undifferentiated cells.
NSC1 cells express neuronal precursor marker NCAM and glial precursor marker A2B5, indicating that both neuronal precursors and glial precursors are present in the NSC1 population. When transferred into a differentiation medium, NSC1 progressed into neurons and GFAP-positive glial cells. As originally reported, 35, 36 ESC-derived NSCs readily generate neurons and astrocytes, but not oligodendro-cytes. It was reported later that oligodendroglial differentiation of these cells requires a growth factor combination of bFGF, plateletderived growth factor and forskolin. 47 The existence of insulin-like growth factor I as a single stimulating molecule may also influence the fate choice of multipotent adult neural progenitor cells to an oligodendroglial lineage. 48 HESC-derived NSC1 cells can be propagated under monolayer culture condition and cryopreserved without losing their NSC properties. NSC1 proliferated for at least 6 months under standard cellculture conditions, yet still maintained their neural multipotency. This sustained proliferative capability is necessary to produce sufficient amounts of cell-based therapeutics in a reproducible manner. Longterm proliferation is also useful for ex vivo genetic modification and selection of the modified cells. As the cells can be expanded in a chemically defined medium, there can be greater control over the quality of NSCs produced.
The strong glioma-specific tropism of NSC1 cells is an attractive feature for targeted gene delivery. In vitro migration assays showed that NSC1 cells migrated specifically to glioma cell lines, with a tropism similar to that of mouse C17.2 cells, the best-studied NSC cell line in animal models. In nude mice, NSC1 cells are able to target intracranial brain tumor after contralateral brain injection or even tail vein injection. Glioma gene therapy clinical trials over the past 10 years have tested adenovirus, retrovirus, HSV-1 and liposome vectors. The results of most of these clinical studies have been poor, and transfection efficiency of these vectors was low in vivo. These poor results were due to the inability to kill tumor cells in situ and the limited distribution of transgene and vectors within the tumor mass. With the demonstrated migratory and tumor-infiltrating feature of the NSC1 cells, these cells can be used to overcome the problems associated with current viral and non-viral vector-based gene therapy approaches by delivering therapeutic genes to disseminated glioma satellites remote from the main tumor mass.
To use stem cells as delivery vectors for cancer therapy, it is essential that these cells can be genetically modified in a safe and effective way to carry therapeutic payloads of interest over the period of time crucial to the therapy. In the current study, we demonstrated for the first time that baculoviral vectors can be used for genetic modification of human NSCs to provide relatively long-term expression of transgenes suitable for cancer therapy. Large cloning capacity, ease of virus production and low cytotoxicity to transduced cells are the obvious advantages associated with the emergence of baculovirus in the gene delivery field. Insect baculovirus also bypasses the risk of virus replication and potential viral infection in host cells, risks borne by conventionally used animal viruses such as adenovirus, retrovirus and adenoassociated virus. Pre-existing host immune response against adenoviral vectors, a type of vectors commonly used for transient transgene expression, is another concern that restricts the use of these vectors. [49] [50] [51] Unlike adenovirus, baculovirus is not targeted by pre-existing immunity in humans. 52 Furthermore, baculovirus transduction has been shown to display no effect on the immunological properties on mesenchymal stem cells, especially the ability of mesenchymal stem cells to evade immune recognition in immunocompetent rats. 53 The transient gene expression mediated by baculovirus of non-integrating nature, however, limits its efficacy in studies that require long-term transgene expression. This limitation is not unique to baculovirus, but is also faced by adenovirus. As demonstrated in the current study, baculovirus-mediated transgene expression could last for at least 3 weeks in human NSCs. After viral expression cassette is optimized, 54 we postulate that the period of transgene expression can be extended further for improved tumor killing. 
L E
To investigate whether hESC-derived NSC1 cells can migrate through brain parenchyma to reach the tumor site and thus can be used in the treatment of disseminated brain tumors, the cells were injected either into the brain side contralateral to the U87 glioma cell inoculation site or intravenously in the present study. Only a portion of the injected cells can home in to the tumor site. For example, 25% of the brain injected cells moved into the U87 glioma side (Figure 3c ), which appear already enough to display therapeutic effects (Figure 7) . The rest of the injected cells will be eliminated by the HSVtk/GCV treatment as demonstrated in Figure 6b . This is considered to be an advantage of using a suicide gene therapy regimen that removes stem cell vehicles to minimize undesired immune reactions associated with the persistent presence of allogeneic cells. As normal brain cells are either non-dividing or at a lower proliferation rate compared with highly proliferating brain tumor cells and proliferating NSCs, they are less sensitive to the killing effects of phosphorylated GCV. In the case of systemic injection of NSCtk for brain cancer therapy, the majority of intravenously injected cells became stuck in the lung and liver because of the narrow diameters of lung capillaries and liver sinusoids. 55 Damaging normal proliferating cells in these organs by the bystander effect of phosphorylated GCV is a major safety concern here. One possible way to alleviate this problem is to develop a new regulation system that triggers transgene expression in NSCs only after they home in on tumors.
In conclusion, we have demonstrated that NSCs derived from hESCs could be recruited to tumors. Coupling hESC-derived NSCs with HSVtk suicide gene expression provides a significant tumor killing effect in a human glioma xenograft mouse model. As large amounts of hESC-derived NSCs could be generated and genetically modified, they are an attractive option for stem cell-based gene therapy. The breakthrough in derivation of human induced pluripotent stem cells provides another possibility for large-scale derivation of human NSCs, an approach that may help bypass the ethical and allogeneic issues posed by the use of hESCs.
MATERIALS AND METHODS Generation and differentiation of NSCs
The NIH Human Embryonic Stem Cell Registry-listed hES cell line HES1 (ES Cell International, Singapore, NIH code: ES01) was cultured on mitotically inactivated mouse embryonic fibroblasts from CF-1 mouse strain obtained from American Type Culture Collection (Manassas, VA, USA) as described. 24 For monoculture differentiation of HES1 cells, 35, 36 hESC colonies were detached from the organ dish 7 days after plating by mechanical cutting. hESCs were dissociated to single cells using trypsin and plated onto a 0.1% gelatin-coated 6-well cell-culture plates (Nalge Nunc International, Rochester, NY, USA) at a density of 10 6 per well and cultured in Dulbecco's modified Eagle's medium (DMEM)/F12(1:1 mixture) medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2% B27 (Invitrogen), 2 mM L-glutamine, 50 U ml À1 penicillin, Figure 7 In vivo targeted glioma therapy using NSC1 cells. (a) U87-luc cells were inoculated into the right striatum of the mouse brain. Seven days later, NSC1-tk cells or PBS was injected contralaterally into the left striatum of the brain (n¼10 per group). From days 14 to 35, GCV (50 mg kg À1 body weight) or PBS was intraperitoneally administered daily. Bioluminescent images of tumor growth in representative animals from each group at days 14, 21 and 28 after U87-luc cell inoculation are shown. Heat map represents the tumor area and color represents the intensity. (b) Quantitative analysis of bioluminescence signals. The y axis is in log scale. Note a significant low level of signal intensity in the group of mice injected with NSC1-tk cells followed by GCV treatment at day 28. Bars: s.d. **Po0.01 vs other groups by analysis of variance. (c) Brain injection of NSC1-tk cells coupled with GCV treatment prolongs life of mice inoculated with U87 glioma cells. The statistical analysis was performed using the log rank test. (d) Representative pictures of brain sections show tumor size in different groups. NSC1-tk brain injection followed by GCV i.p. injection appears to shrink the tumor. In the three control groups, NSC1-tk brain injection followed by PBS i.p. injection, PBS brain injection followed by GCV i.p. injection and PBS brain injection followed by PBS i.p. injection, large and grossly visible tumor masses were found. 50 mg ml À1 streptomycin, 20 ng ml À1 bFGF (Sigma-Aldrich, St Louis, MO, USA) and 20 ng ml À1 EGF (Invitrogen). Half of the cell-culture medium was changed every 2 days and cells were split at 1:2 when reached 90% confluence using TrypLE Express Dissociation Enzyme (Invitrogen). After 1 month of passaging, homogenous bipolar NSCs were achieved and named NSC1.
For passaging established NSCs, cells were treated with TrypLE and subcultured twice weekly at a split ratio of 1:2. To induce neural differentiation, NSC1 cells were transferred to uncoated, low-cell binding 6-well plates (Nalge Nunc) in the above NSC culture medium. After culturing for 1-3 weeks, round neurospheres were formed. The spheres were then plated into poly-D-lysine (Sigma-Aldrich) and laminin (Sigma-Aldrich) coated dishes. Neuronal and glial differentiation was induced by the withdrawal of EGF and bFGF from the culture medium. Human stem cell RT 2 Profiler PCR Arrays (PAHS-405; QIAGEN, Valencia, CA, USA) were used to screen the expression of stem cell differentiation markers. The assays were performed with SYBR Green technology according to the manufacturer's protocol. The thermal cycling conditions included an initial step of 10 min at 95 1C, followed by 40 cycles at 95 1C for 15 s each, and then 60 1C for 1 min with fluorescence detection. The initial 10 min at 95 1C was required to activate the HotStart DNA polymerase. Melt curves were produced using the following steps: 1 min at 95 1C, followed by 1 min at 55 1C, followed by 80 cycles at 55 1C for 15 s with fluorescence detection.
Characterization of NSCs
Reverse transcription-PCR was performed using forward and reverse primers as follows: Oct-4, 169 bp, 5¢-CTTGCTGCAGAAGTGGGTGGAGGAA-3¢ (forward) and 5¢-CTGCAGTGTGGGTTTCGGGCA-3¢ (reverse); Nanog, 426 bp, 5¢-GCGCGGTCTTGGCTCACTGC-3¢ (forward) and 5¢-GCCTCCC AATCCCAAACAATACGA-3¢ (reverse); Brachyury T, 284 bp, 5¢-CAACCACC GCTGGAAGTAC-3¢ (forward) and 5¢-CCGCTATGAACTGGGTCTC-3¢ (reverse); AFP, 675 bp, 5¢-AGAACCTGTCACAAGCTGTG-3¢ (forward) and 5¢-GACAG CAAGCTGAGGATGTC-3¢ (reverse); b-actin, 513 bp, 5¢-GCCCAGAGCAAGA GAGGCAT-3¢ (forward) and 5¢-GGCCATCTCTTGCTCGAAGT-3¢ (reverse).
Migration assay
In vitro migration assays used human U87 MG (ATCC) and H4 (ATCC) glioblastoma cell lines and 293FT cell line (Invitrogen) as attractants and performed in Boyden chambers with the BD Falcon HTS FluoroBlok 96-Multiwell Insert System with 8 mm pore size (BD Biosciences). One day before the assays, glioma cells were suspended in serum-free Opti-MEM (Invitrogen) and seeded into a 96-well companion plates (BD Falcon, San Jose, CA, USA) at a cell density of 6.4Â10 4 per well. NSCs were labeled with Calcein-AM (Invitrogen). The labeled stem cells were suspended in serum-free Opti-MEM and seeded into Boyden chamber transwell inserts at a cell density of 2.5Â10 4 per insert. After 24 h of culture at 37 1C in 5% CO 2 , the fluorescence from the bottom side of the plates (corresponding to migrating cells) was measured using a microplate reader. All experiments were conducted in quadruplicate and values were expressed as mean ± s.d.
For in vivo migration assays, adult female BALB/c athymic, immuno-incompetent nude mice (weight 20 g; aged 6-8 weeks) were used. To generate an intracranial glioma model, U87 cells or green fluorescent carbocyanine dye DiO (Invitrogen)-labeled U87 cells (5Â10 5 cells in 1 ml PBS) were injected into the right hemisphere of the mouse brain. On day 7 post-tumor inoculation, the nearinfrared fluorescent cyanine dye DiR (Caliper Life Sciences, Hopkinton, MA, USA) or red fluorescent dye CM-DiI (Invitrogen)-labeled NSC1 cells (1Â10 6 in 1 ml PBS) were injected into the contralateral hemisphere in the same way. Alternatively, CM-DiI-labeled NSC1 cells (5Â10 6 in 200 ml PBS) were injected into the tail vein. Ex vivo brain imaging of DiR-labeled NSC1 cells was acquired by IVIS imaging system coupled with cool CCD camera (Caliper Life Sciences). For histological examination, mice were killed by cardiac perfusion with PBS, followed by 4% paraformaldehyde in PBS. The brains were harvested, suspended in 30% sucrose and embedded in a tissue-freezing medium. Cryostat sections were prepared and observed under fluorescent microscopy. For immunohistochemistry analysis, the tissue sections were washed twice with Tris-Buffered Saline Tween-20 and incubated in 0.025% Triton X-100 for 10 min. The tissue sections were incubated with 0.3% H 2 O 2 for 10 min to block endogenous peroxidase activity. The tissue sections were then incubated in 5% bovine serum albumin for 1 h to block non-specific binding sites. The mouse monoclonal anti-GFAP antibody (Sigma-Aldrich, 1:100) was applied overnight at 4 1C. After three times washing with Tris-Buffered Saline Tween-20, slides were incubated with the secondary antibody, HRP-conjugated goat anti-mouse IgG (1:200) for 1 h at room temperature. GFAP staining was developed by 3,3¢-diaminodbenzidine substrate and the nucleus was counterstained by hematoxylin.
Baculovirus preparation and cell transduction
Baculoviral vectors with the eGFP reporter gene and HSVtk gene were constructed in our previous study. 24, 25, 27, 42 Viruses were produced and propagated in Sf9 insect cells according to the manual of Bac-to-Bac Baculovirus Expression System (Invitrogen). Budded viruses in the insect cell-culture medium were centrifuged at 2000 g for 10 min to remove cell debris, and concentrated by a second round of centrifugation at 28 000 g for 60 min. Virus pellets were resuspended in 0.1 M PBS and their plaque forming units were determined by plaque assay on Sf9 cells. For baculoviral transduction, cells were transduced in at a multiplicity of infection of 100, and left to incubate overnight. This is followed by a full change of medium the next day to stop transduction. To confirm HSVtk gene expression, reverse transcription-PCR was performed using the forward primer 5¢-CAATCGCGAACATCTACACCA CA-3¢ and the reverse primer 5¢-CCGAAACAGGGTAAATAACGTGTC-3¢ to detect a 593-bp fragment. Recombinant DNA procedures follow the National Institutes of Health guidelines. 
R E T R A C T E D A R T I C L E

Cytotoxicity assays
To evaluate the sensitivity of HSVtk-expressing cells to GCV, cells were seeded in a 96-well cell-culture plate at a density of 1000 cells per well and treated with GCV at concentrations of 0, 0.1, 1 and 10mg ml À1 for 7 days. The GCVcontaining medium was changed every 2 days. To evaluate in vitro bystander effects, HSVtk-expressing cells were co-cultured with U87 cells at a ratio of 1:1 and treated with GCV as described. Cell viability was determined by CellTiter 96 AQueous Assay using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS; Promega). The relative cell growth (%) compared with control cells (cells without GCV treatment) was calculated by (absorbance of sampleÀabsorbance of blank)/ (absorbance of controlÀabsorbance of blank)Â100%.
Animal studies to evaluate therapeutic efficacy
To investigate in vivo therapeutic bystander effect, the stable U87 cell clone expressing luciferase gene (U87-luc) was used. These cells were generated as described 27 and maintained with 500 mg ml À1 geneticin. U87-luc cells (1Â10 5 cells in 1 ml PBS) were injected into the right hemisphere in nude mice as described above. On day 7, baculovirus-transduced, HSVtk-expressing NSCs (10 6 in 1 ml PBS) or 1 ml PBS were injected into the contralateral hemisphere. Animals were intraperitoneally administered 50 mg ml À1 GCV (50 mg kg À1 body weight) or PBS daily from days 14 to 35 post-tumor inoculation. All together, four groups (n¼10 per group) were tested: brain injection of PBS followed by PBS i.p. injection, brain injection of PBS followed by GCV i.p. injection, brain injection of NSCs followed by PBS i.p. injection and brain injection of NSCs followed by GCV i.p. injection. To monitor bioluminescence signals of U87-luc cells, isoflurane gas-anesthetized animals were injected intraperitoneally with D-luciferin (Promega) at 100 mg kg À1 in PBS and placed on a warmed stage inside the camera box of the IVIS imaging system coupled with cool CCD camera (Xenogen, Alameda, CA, USA). The detected light emitted from U87-luc cells was digitized and electronically displayed as a pseudocolor overlay onto a grayscale image of the animal. Images and measurements of luminescent signals were acquired and analyzed with the Xenogen living imaging software v2.5 and quantified as photons per second. All handling and care of animals were carried out according to the Guidelines on the Care and Use of Animals for Scientific Purposes issued by the National Advisory Committee for Laboratory Animal Research, Singapore.
Statistical analysis
All data are represented as mean±s.d. The statistical significance of differences was determined by the two-factor analysis of variance with replication followed by Fisher's least significant difference post hoc analysis. The statistical analysis of survival data was performed using the log rank test followed by Holm-Sidak method for pairwise multiple comparison tests. A P-value of o0.05 was considered to be statistically significant.
